Press releases worldwide
Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, bringing deep industry knowledge, international experience and expertise in leading […]
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM) Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability Customers can […]
In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a margin of 33.1% H1 2022 CAPEX reached 28.2% of sales as Lonza continues to execute planned investments Group Outlook […]
. Lonza appoints Maria Soler Nunez as Head, Group Operations Maria joins Lonza from Novartis where she has led the quality organization since 2020 Maria will commence her tenure with Lonza Group on 1 August 2022, succeeding Stefan Stoffel, who […]
. Purpose-built bioconjugation facility in Lonza’s Ibex® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak’s lead product candidate KSI-301 for high-prevalence retinal diseases The opening ceremony took place on May 17, 2022 following mechanical completion […]
Shareholders re-elected all existing members of the Board of Directors who stood for re-election and elected Marion Helmes and Roger Nitsch as new members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of […]
. Annual General Meeting to take place on 5 May 2022 at the company’s headquarters in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of Directors Stable dividend of CHF 3.00 per share proposed 2021 […]
. Lonza appoints Christian Seufert as President of the CHI Division and member of the Executive Committee Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses He will commence […]
Lonza delivers CHF 5.4 billion sales and 20% CER1 sales growth CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8% 2021 CAPEX reached 24% of sales, supporting long-term plan to deliver attractive margins through de-risked growth investments Continuing focus […]
Lonza to acquire Exosomics Service Unit in Siena, Italy to expand development service offering in exosome bioprocessing Expertise in exosomes isolation and characterization will drive innovation in this field Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutrition […]